Document Detail


Diclazuril Protects against Maternal Gastrointestinal Syndrome and Congenital Toxoplasmosis.
MedLine Citation:
PMID:  24851194     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Toxoplasmosis is a common cause of foodborne, gastrointestinal and congenital syndrome with particularly severe or unknown health consequences. There is no safe and effective preventive or therapeutic modality against congenital toxoplasmosis or to eliminate the persistent chronic infection.
HYPOTHESIS: Diclazuril to be safe in pregnancy and effective against gastrointestinal toxoplasmosis.
METHODS: CD1 programmed pregnant mice were divided into groups and administered a diet containing diclazuril, or sham control. Treatments were initiated on Day 5 of pregnancy and continued until Day 16 when dams were euthanatized. On Day 8 of pregnancy dams were infected intraperitoneally with escalating doses of tachyzoites (0, 100, 300, 600) from Type II strain. Dams were monitored daily for distress, pain, and abortion and samples collected at the end of the experiments.
RESULTS: Infected dams developed moderate to severe Toxoplasma related complications in tachyzoites dose dependent manner. Animals became anemic and showed hydrothorax, and ascities. Diclazuril effectively protected dams from ascities and anemia (p < 0.05). Infected dams showed splenomegaly, with massive infiltration of epithelioid cells compared with the protective effect of diclazuril in treated animals. Infected dams exhibited severe hepatitis (score 0 to 4 scale = 3.5 ± 0.01) with influx of inflammatory and plasma cells, dysplastic hepatocytes, multinucleated giant cell transformation and hepatic cells necrosis. Diclazuril treatment significantly protected dams from hepatitis, also in tachyzoites dose (100, 300, 600) dependent manner (respectively infected-treated versus infected controls, p < 0.001, p < 0.01 and p < 0.05). Colonic tissues were significantly shortened in length, with infiltration of lymphocytes, and macrophages and microabscess formations in the cryptic structures, with significant improvement in diclazuril treated animals. Additionally, the number of fetuses, fetal length and fetal weight were preserved in diclazuril treated dams.
CONCLUSIONS: This is the first report describing of diclazuril safety in pregnancy as well as efficacy against mild to moderate hepato-gastrointestinal syndrome in dams and fetal toxoplasmosis (Special issue, "Treatment of Liver Diseases").
Authors:
Helieh S Oz; Thomas Tobin
Related Documents :
7977544 - Acute fatty liver of pregnancy: an experience in the diagnosis and management of fourte...
332324 - Consequences of acute myelogenous leukemia in early pregnancy.
23658134 - Long-term neurodevelopmental and cardiovascular outcome after intrauterine transfusions...
14587894 - Water quality guidance for protection of freshwater mussels (unionidae) from ammonia ex...
6397784 - Hepatic drug metabolism in pregnancy.
8573964 - Cisapride for the treatment of chronic idiopathic constipation.
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  International journal of clinical medicine     Volume:  5     ISSN:  2158-284X     ISO Abbreviation:  Int J Clin Med     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-5-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101571689     Medline TA:  Int J Clin Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  93-101     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diagnostic Utility of Gene Expression Profiles.
Next Document:  Considering Factors of and Knowledge About Patients in Handover Assessment.